secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2025-12-02T23:59:59+00:00
Accession:  0001213900-25-116943
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper reports positive ETESIAN asthma data; BEACON investigation clears drug product
--------------------------------------------------------------------------------

- Single 180mg briquilimab reduced sputum eosinophils from 10.3% to 2.32% at 6 weeks post-allergen challenge.
- Late asthmatic response FEV1 AUC improved 25.4% at 6 weeks and 23.3% at 12 weeks vs baseline.
- BEACON investigation: no drug product issues; 9 of 10 US patients likely did not have mast cell-driven CSU.
- Briquilimab well-tolerated; no dose-limiting toxicities; safety profile consistent with prior studies.
- Final BEACON data expected Q1 2026; Phase 2b CSU study planned to start mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390025116943/0001213900-25-116943-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390025116943/ea0268071-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-116943

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer